Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Qishen Yiqi Dropping Pill for diastolic dysfunction in hypertension with left ventricular hypertrophy
ChiCTR2300070084Phase 4Not yet recruiting
- Sponsor
- Peking University First Hospital
- Start
- Apr 2023
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of qishen yiqi dripping pills in hypertension (HTN) (3 arms), sponsored by Peking University First Hospital. Primary endpoint: Change in E/e' and between-group difference. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
qishen yiqi dripping pills
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on ChiCTR2300070084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070084.